Business Wire

HOUSE-WELLNESS-FOODS

3.5.2016 13:51:54 CEST | Business Wire | Press release

Share
First-Ever Published Study Proves House Wellness Foods’ Feed LP20® Increases Immunity, Productivity of Whiteleg shrimp [L. vannamei]

A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, reversing disease trends and increasing reproduction. The study, published in the International Journal of Scientific and Research Publications , Volume 6, Issue 3, March 2016, is welcome news for the East Asian fishing industry, which has been plagued by vibriosis, linked to the presence of Vibrio parahaemolyticus and other bacteria found in salt water. Feed LP20® is proven safe, and represents groundbreaking evidence of the effectiveness of heat-treated lactobacillus, as measured in conjunction with this crucial species.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160503005537/en/

Feed LP20® was developed for livestock and fisheries as an alternative to antibiotic regimens, and as a functional product for improving immune function and productivity. It contains 20% heat-killed Lactobacillus plantarum L-137 (HK L-137) . Heat treatment of HK L-137, the central ingredient of House Wellness Foods’ Feed LP20® and Immuno-LP20® , is key to those products’ effectiveness, making them stable long-term at varying temperatures, easily handled, even under pressure, and maintaining immunostimulant properties while resisting degradation by water and gastric acids.

HWF is regarded as a pioneer in the continuous study of HK L-137, and Immuno-LP20 has been hugely successful as an immunobiotic, enjoying prominence among health-conscious consumers in the U.S. and worldwide as a natural aid to the body’s innate ability to defend itself against seasonal illness and allergy.

A joint study conducted in cooperation with Vietnam’s Can Tho University proved conclusively that the addition of as little as 100 ppm of Feed LP20 boosts immune function in the shrimp population and improves survival and growth rates, which were significantly (P<0.05) higher compared to other feeds. Immune parameters consisted of total haemocyte count, differential haemocyte count, phenoloxidase activity, phagocytic activity and clearance efficiency. The study also showed a critical synergistic effect in conjunction with B-glucan, an activator of immune system functions in aquaculture.

House Wellness Foods is pursuing sales and promotion of Feed LP20 for livestock and aquaculture in support of these industries and in the hope of ameliorating the blight of worldwide hunger.

Contact:

House Wellness Foods
Onoda Satoru, +81-3-5211-7220
Onoda_Satoru@house-wf.co.jp

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye